^
    4ms
    Agilent MMR IHC Panel pharmDx (Dako Omnis) Receives FDA Approval as a Companion Diagnostic Test for Colorectal Cancer (Businesswire)
    "This test aids in identifying mismatch repair deficient (dMMR) colorectal cancer (CRC) patients who are eligible for treatment with Bristol Myers Squibb’s Opdivo (nivolumab) alone or Opdivo (nivolumab) in combination with Yervoy (ipilimumab)."
    FDA approval
    |
    Dako c-KIT pharmDx
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)